Lexicon Pharmaceuticals, Inc

Lexicon Pharmaceuticals, Inc

Lexicon Pharmaceuticals, Inc company was founded in 1995 and is headquartered in The Woodlands, Texas. Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which is in a Phase II clinical trial for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX1032 that has completed Phase I clinical trials to treat the symptoms associated with carcinoid syndrome; LX2931, which is in Phase I clinical trial for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX4211 that is in Phase 1 clinical trials to treat Type 2 diabetes. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. Lexicon Pharmaceuticals has drug discovery alliances with Bristol-Myers Squibb Company to discover, develop, and commercialize small molecule drugs in the neuroscience field; and N.V. Organon to discover, develop, and commercialize new biotherapeutic drugs. It also has an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.

Contact Details

Office Address

Lexicon Pharmaceuticals, Inc
The Woodlands, TX Corporate Headquarters 8800 Technology Forest Place
The Woodlands, TX, USA 77381-1160
Phone: (281) 863-3000
Fax: (281) 863-8088

Executives

Co-Founder & Chief Exec. Officer

Mr. Arthur T. Sands

Co-Founder & Chief Scientific Officer

Dr. Brian P. Zambrowicz

Business Reviews for Lexicon Pharmaceuticals, Inc

Related Companies